About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Familial Systemic Scleroderma | Clinical Trials | Clareo Health

Back to clinical trial search

RECRUITINGNCT07343115

Familial Systemic Scleroderma

Studying familial forms of systemic scleroderma offers several advantages: 1. To better understand the pathophysiology of a complex autoimmune disease based on "extreme" cases (familial forms); 2. To...

Lead sponsor: University Hospital, Strasbourg, France•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Aurélien GUFFROY, MD

CONTACT

33 3 69 5512 23 aurelien.guffroy@chru-strasbourg.fr

Sponsors

Lead Sponsor

University Hospital, Strasbourg, France

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Adult subjects (≥ 18 years of age)
•Subjects diagnosed with systemic scleroderma by a clinician (including limited, diffuse, and sine scleroderma SSc, as well as overlap syndromes with myositis) and meeting at least the VEDOSS criteria: Raynaud's phenomenon + 1 other criterion from among: sausage fingers, antinuclear antibodies, scleroderma-specific antibodies (anti-centromere, anti-RNApolIII, anti-ScL70), capillaroscopic abnormalities
•At least one first-degree relative with systemic scleroderma meeting the same criteria

Exclusion Criteria

•\- Subject who has expressed opposition to participating in the study

Related studies

Diffuse Cutaneous Scleroderma (DSSc) SFDI Study

NCT07090226 · Systemic Scleroderma, Diffuse Cutaneous Scleroderma

Active Not RecruitingPhase 3

Clinical Study of Divozilimab in Patients With Systemic Scleroderma

NCT05726630 · Systemic Scleroderma

Not Yet RecruitingPhase 2

Efficacy and Safety of Allogenic Cultured Adipose-derived Mesenchymal Stromal Cell Injections on MoUth Fibrosis and Handicap in Patients With Systemic sclEroderma

NCT07326033 · Systemic Scleroderma

Role of Eosinophil in Fibrogenesis of Systemic Sclerosis

NCT03816189 · Systemic Sclerosis, Systemic Scleroderma

Evaluation of the Serum Soluble Fractalkine as a Biomarker of Pulmonary Fibrosis in Systemic Sclerosis

NCT03508375 · Systemic Scleroderma

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: January 15, 2026Terms

Trial snapshot

StatusRECRUITING

Phase—

Enrollment20

Start dateSep 2025

Last updatedJan 15, 2026

Condition

Systemic Scleroderma

Locations shown

Service de Médecine interne et Immunologie clinique - CHU de Strasbourg - France

Strasbourg

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 15, 2026Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions